Zwolle

• A phase 3 study to Evaluate the Efficacy and Safety of HLX10 or placebo in Combination With Chemotherapy and Radiotherapy in Patients With L … Ended recruitment
  2024-515047-31-00 5 2023-08-28 Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) at stage
• A Study to Examine the Efficacy and Safety of ZX008 in Subjects with CDKL5 Deficiency Disorder Ended recruitment
  2023-506269-78-00 5 2023-06-20 CDKL5 Deficiency disorder
• A Phase 3, 52-Week, Randomized, Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory or Une … Ended recruitment
  2024-513460-26-00 5 2023-03-29 Refractory Chronic Cough, Including Unexplained Chronic Cough
• Does progesterone luteal phase support increase live birth rates in couples undergoing intra-uterine insemination with Mild Ovarian HyperSti … Ended recruitment
  2022-501534-33-00 6 2023-03-06 Unexplained Subfertility, infertility
• Master Protocol for Encorafenib/Binimetinib Continuation Sub-Studies (FLOTILLA Study) Ended recruitment
  2023-509408-13-00 6 2022-09-20 Solid tumors
• LEGACY Ended recruitment
  2023-504360-42-00 6 2022-05-13 Non-ST-segment elevation acute coronary syndrome
• A Phase 3 Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant Ended recruitment
  2023-508897-27-00 5 2022-04-28 Multiple Myeloma
• Clinical Trial of MK-7684A with chemotherapy for extensive stage small cell lung cancer (ES-SCLC) Ended recruitment
  2023-503517-30-00 5 2022-04-01 Extensive-stage small-cell lung cancer
• Personalized dosing of ocrelizumab in MS Ended recruitment
  2024-513193-22-00 11 2022-03-16 Multiple Sclerosis
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexa … Ended recruitment
  2023-503441-55-00 4 2021-10-14 Relapsed/Refractory Multiple Myeloma
• NADINA Ended recruitment
  2024-513519-28-00 5 2021-07-23 Stage III melanoma
• Induction chemotherapy for locally advanced rectal cancer. Ended recruitment
  2023-509758-74-00 4 2021-07-21 Locally advanced rectal cancer
• A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine ( REBUILD-2 ) Ended recruitment
  2023-505835-11-00 5 2021-03-12 Chronic Migraine
• A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine ( REBUILD-1 ) Ended recruitment
  2023-505836-36-00 5 2021-03-12 Migraine
• Iberdomide as maintenance therapy after autologous stem cell transplantation in newly diagnosed multiple myeloma patients Ended recruitment
  2024-512354-21-00 4 2021-02-22 Newly diagnosed multiple myeloma
• A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab … Ended recruitment
  2022-500439-35-00 5 2021-02-11 treatment-naive chronic lymphocytic leukemia
• Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants with Advanced NSCLC … Ended recruitment
  2023-507475-21-00 10 2021-01-18 Lung Cancer, Non-Small Cell
• A clinical study of belzutifan for treatment of kidney cancer (MK-6482-013) Ended recruitment
  2022-502123-21-00 4 2020-12-08 Advanced Renal Cell Carcinoma
• Safe shortening of antibiotic treatment duration for complicated Staphylococcus aureus bacteremia (SAFE-trial) Ended recruitment
  2024-515398-90-01 5 2020-08-17 Staphylococcus aureus bacteremia
• A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit … Ended recruitment
  2023-508292-37-00 5 2020-03-06 Cardiovascular Disease
• HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended recruitment
  2022-502478-18-00 4 2019-12-20 Acute Myeloid Leukemia (AML)
• A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine in unfit … Ended recruitment
  2023-503829-18-00 4 2019-12-05 Acute myeloid leukemia
• Liposomal iRInotecan, Carboplatin or oXaliplatin in the first line treatment of esophagogastric cancer: a randomized phase 2 study (LyRICX) Ended recruitment
  2023-509287-26-00 4 2019-07-01 previously untreated metastatic or locally advanced esophagogastric ca
• Image‐guided de‐escalation of neoadjuvant chemotherapy in HER2‐positive breast cancer: the TRAIN‐3 study Ended recruitment
  2024-516205-23-00 4 2019-04-09 Breast cancer

Showing 121–144 of 191 trials